ZYME Logo

Zymeworks Inc. (ZYME) 

NYSE
Market Cap
$1.07B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
776 of 776
Rank in Industry
433 of 433

Largest Insider Buys in Sector

ZYME Stock Price History Chart

ZYME Stock Performance

About Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or …

Insider Activity of Zymeworks Inc.

Over the last 12 months, insiders at Zymeworks Inc. have bought $0 and sold $436,288 worth of Zymeworks Inc. stock.

On average, over the past 5 years, insiders at Zymeworks Inc. have bought $16.77M and sold $2.47M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,350,000 shares for transaction amount of $27.2M was made by EcoR1 Capital, LLC (10 percent owner) on 2023‑06‑16.

List of Insider Buy and Sell Transactions, Zymeworks Inc.

2024-01-08SaleChair & CEO
5,706
0.0079%
$11.22$63,996-8.67%
2024-01-08SaleChief Scientific Officer
2,339
0.0033%
$11.22$26,233-8.67%
2024-01-08SaleSVP & Chief Financial Officer
1,431
0.002%
$11.22$16,050-8.67%
2024-01-05SaleChair & CEO
18,198
0.0262%
$10.65$193,849-0.14%
2024-01-05SaleChief Scientific Officer
7,460
0.0107%
$10.65$79,465-0.14%
2024-01-05SaleSVP & Chief Financial Officer
4,563
0.0066%
$10.65$48,606-0.14%
2023-12-11SaleSVP & Chief Financial Officer
886
0.0013%
$9.13$8,089+13.98%
2023-06-16Purchase10 percent owner
3.35M
5.0195%
$8.12$27.2M+7.27%
2023-03-28Purchase10 percent owner
200,000
0.2981%
$8.00$1.6M+6.44%
2023-03-10SalePresident & COO
2,977
0.0044%
$7.83$23,298+6.56%
2023-01-20Purchasedirector
163,400
0.2428%
$9.88$1.62M-16.45%
2023-01-19Purchasedirector
144,100
0.2124%
$9.49$1.37M-13.66%
2023-01-18Purchasedirector
203,000
0.3051%
$10.00$2.03M-16.43%
2023-01-17Purchasedirector
440,000
0.6486%
$9.80$4.31M-16.43%
2023-01-13Purchasedirector
342,100
0.5024%
$9.81$3.35M-16.78%
2023-01-11Purchasedirector
106,300
0.1527%
$7.87$836,911+1.43%
2023-01-10Purchasedirector
920,000
1.3565%
$7.65$7.04M+7.02%
2022-11-10SaleChief Medical Officer
2,475
0.0037%
$8.10$20,045-2.32%
2022-10-13Purchase10 percent owner
30,481
0.0481%
$5.03$153,435+63.80%
2022-03-10SaleChief Operating Officer
2,979
0.0048%
$6.88$20,496-6.14%

Insider Historical Profitability

<0.0001%
EcoR1 Capital, LLC10 percent owner
13437473
19.5092%
$15.5690<0.0001%
Redmile Group, LLC10 percent owner
6075918
8.8213%
$15.5610+63.8%
Tehrani AliChief Executive Officer
260325
0.378%
$15.5616+12.44%
Josephson NeilChief Medical Officer
14449
0.021%
$15.5611<0.0001%
Cox Troydirector
7500
0.0109%
$15.5610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$141.36M19.0113.44M0%+$00.99
Bvf Inc Il$61.75M8.35.87M0%+$00.45
Redmile Group$58.5M7.875.56M-3.96%-$2.41M0.6
Morgan Stanley$53.77M7.235.11M+5.14%+$2.63M<0.01
BlackRock$43.09M5.794.1M+4.39%+$1.81M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.